News Releases

All Years	
Search	
	Go
Advanced Search	
And the second secon	OCT 12, 2021 INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates the Potential to Achieve Normal Alpha-1 Antitrypsin Levels with Monthly Dosing

OCT 11, 2021 Inhibrx To Host Webcast Presentation of Interim Results from the Phase 1 Trial of INBRX-101, its Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency

SEP 13, 2021 Inhibrx Announces Participation in Upcoming Investor Conference

AUG 9, 2021 Inhibrx Reports Second Quarter 2021 Financial Results

JUN 21, 2021

Inhibrx Initiates a Potential Registration-Enabling Phase 2 Study of INBRX-109 in Conventional Chondrosarcoma Patients, Updates Data for Ongoing Phase 1 Study and Announces Amended Loan

MAY 17, 2021 Inhibrx Announces Participation in Upcoming Investor Conferences


MAY 13, 2021 Inhibrx Reports First Quarter 2021 Financial Results

MAR 12, 2021 Inhibrx Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Announces Phase 1 Single Agent Dose Escalation Results for INBRX-105, a Novel Targeted 4-1BB Agonist

FEB 1, 2021 Inhibrx Announces Participation in Upcoming Investor Conference

JAN 13, 2021 Inhibrx Granted Fast Track Designation for INBRX-109 for the Treatment of Unresectable or Metastatic Conventional Chondrosarcoma Patients

Show 10 🗸 per page





https://inhibrx.investorroom.com/news-releases?I=10&o=40